A 3-year-old girl with BCR/ABL-positive CML relapsed after related HLA-identical cord blood transplantation. She was treated with three cycles of donor lymphocyte (DLI) infusion from her 15-month-old brother. Interferon ␣ was added after the second DLI, whereas a trial of IL-2 had to be discontinued because of increasing immature myeloid cells in the blood smear. No signs of GVHD were observed, but she developed myelosuppression and needed one platelet and one red blood cell transfusion. She achieved a molecular remission after 6 months with transient molecular relapse followed by sustained remission for 15 months. Thus, DLI with or without interferon alpha might prove to be a promising treatment option with tolerable side-effects in relapsed CML after cord blood transplantation. Bone Marrow Transplantation (2000) 25, 219-222.
after CBT might be associated with an increased risk of relapse. 4 However, the most recently published clinical follow-up points to the contrary. 5 Donor lymphocyte infusion (DLI) is considered to be the treatment of choice in patients with relapse of CML after BMT. 7, 8 Some patients with relapsed CML responded only to DLI following in vivo or in vitro activation by cytokines. [9] [10] [11] There are very few reports about treatment strategies in patients who relapse after CBT 12, 13 but they include one case report of DLI used in a successful therapeutic trial in a boy with relapse of ALL after CBT. 12 The present case report describes successful DLI combined with cytokine treatment in a 3-year-old girl with relapsed CML 7 months after HLA-identical CBT from her brother. She was treated with three DLI: once alone and twice later combined with IFN␣.
Case report
BCR/ABL-positive adult CML was diagnosed in a 17-month-old girl with splenomegaly, leukocytosis and thrombocytosis. She was initially treated with hydroxyurea and interferon-alpha (IFN␣) until the white blood cell (WBC) count and differential count normalized. Afterwards, hydroxyurea was given for at least 12 months. A HLA-identical brother was born 4 months after confirmation of the diagnosis. His umbilical cord blood was collected and frozen as described previously. As the patient was in a good clinical condition with normal WBC and differential count whilst on hydroxyurea, CBT was delayed until her brother would have been able to donate bone marrow in case of graft failure after CB infusion.
The preparative regimen for CBT consisted of busulfan 4 mg/kg bw, delivered as 4 daily doses over a period of 4 days (total dose 16 mg/kg bw) and cyclophosphamide 120 mg/kg bw over 2 days. On day 0 the CB was thawed as described previously. 14 GVHD prophylaxis consisted of cyclosporin A (CsA) alone and was started on day −1, with 3 mg/kg bw. The dosage was consecutively adapted to reach serum trough levels between 100 and 200 ng/ml. GVHD prophylaxis was ended on day 150 post CBT.
The patient received granulocyte colony-stimulating factor post transplantation for 27 days. Stable neutrophil counts Ͼ500/l were achieved on day 19, the last platelet transfusion was given on day 37 and the last red cell transfusion on day 41 post CBT. For three days, from day 19 to 21, a single episode with symptoms of acute cutaneous GVHD was observed with an erythematous-macular rash on the palms of both hands and small, spotted, confluent efflorescences on the back. These symptoms completely resolved when CsA serum trough levels were raised from 80 ng/ml to 200 ng/ml.
At various time points post CBT, chimerism analyses were performed by variable number tandem repeats (VNTR) analysis (J Henke, Institute for Investigation of Blood Group, Cologne, Germany) and/or by FISH detection of Y chromosome-positive cells in the peripheral blood (PB) and/or bone marrow (BM). 15 Post DLI, when VNTR analysis showed that the patient's DNA was Ͻ2%, additional determination of the BCR-ABL ratio was performed to detect minimal residual disease (A Hochhaus MD, Department of Internal Medicine, Mannheim, Germany).
Forty days post CBT, 97.5% donor cells were detected by VNTR in BM. Complete chimerism in PB was observed on days 100 and 173. However, on day 190 post CBT the CML relapsed. The BM aspiration contained approximately 7% recipient DNA, and in 10% of the interphase cells two X chromosomes were present. These findings were confirmed by PCR analysis detecting again the BCR/ABL transcript. Over the next weeks peripheral leukocyte and thrombocyte counts increased and donor cells dropped (see Figure 1 ). We therefore decided to treat the patient with donor lymphocyte infusions (DLI).
After obtaining parental informed written consent, Time course of donor DNA in peripheral blood in a 3-yearold girl with CML after cord blood transplantation (a). Three weeks after diagnosis of relapse, she received the first donor lymphocyte infusion. The second DLI was combined with IL-2 for 2 days. Because of increasing leukocyte counts with more immature myeloid cells in peripheral blood during IL-2 infusion, this was discontinued and IFN␣ s.c. was given. In minimal residual disease analysis (b), molecular remission was reached 6 months after the third DLI.
donor-derived DLI were performed on days +228, +248 and +264 post CBT (for details see Table 1 ). Each time 50 ml of blood were collected from the 15-month-old brother without particular problems. The first DLI was administered without further manipulation. After this first DLI the recipient developed a Coombs' reactive antibody against the donor's erythrocytes. Because of blood group disparity between donor (A1) and recipient (A2) an irregular A1 antibody was suspected. Therefore, the second and third DLI were given as red cell-depleted preparations.
After the first DLI we observed an increase in BCR/ABL-positive host cells. Therefore we combined the second DLI with IL-2 in order to optimize antileukemic activity mediated by T and NK cells. IL-2 was given as an i.v. continuous injection with 6 × 10 6 U/m 2 /day for the first day which was increased to 9 × 10 6 U/m 2 /day for the second day. After 2 days, leukocyte and immature myeloid cells counts increased. Therefore, a treatment with 2 × 10 6 U IFN␣ per day s.c. was initiated for 42 days. One week later a second low dose application of 100 000 U IL-2 s.c. was performed while IFN␣ was continued. Once again, with increasing immature myeloid cell counts the IL-2 administration was discontinued.
Hemoglobin levels, leukocytes due to reduced neutrophil counts, monocytes and thrombocytes decreased 70 days after the first DLI and 1 month after the third DLI. T cell number and activation were low before starting DLI but increased after DLI (data not shown) and remained within the normal range of our internal laboratory data. 16 Six weeks after the third DLI, IFN␣ was reduced to an alternate day schedule and stopped 2 weeks later. At this time point, the WBC was 3100/l with a normal differential count. During and after the DLI treatment only one platelet and one red cell transfusion were necessary. Since day +364 post CBT the patient is in cytogenetic remission, with the last DNA being Ͻ1% host-derived as determined by VNTR in peripheral blood. The ratio of BCR-ABL/ABL decreased from 0.59% to 0.075% on day +365 and day +406 respectively post CBT, rose again to 1.4% on day 461 and dropped to 0.001% on day +497. Until now, 15 months after the third DLI, the patient is in good clinical condition without further treatment, with total hematopoetic recovery and normal blood values.
Discussion
This case report confirms that DLI from a 15-month-old donor after related CB transplantation is feasible and may be curative in relapsed CML after sibling CBT. A general concern about the possibility of an increased risk of leukemic relapse in CB recipients is based on the classical observation that there is a close association of GVL with GVHD in allograft recipients. Patients developing either acute or chronic GVHD have a much lower risk of relapse. 17 Since incidence as well as severity of both acute and chronic GVHD apeared to be considerably lower after transplantation of cord blood progenitors than after marrow transplantation, [4] [5] [6] 17, 18 the apparent immaturity of infused cord blood lymphocytes 19 theoretically could impair the GVL effect. There is very limited experience with treatment strategies for relapses after CBT. 12, 13 Especially after allogeneic BMT, relapse is associated with a poor prognosis, since further chemotherapy and a second bone marrow transplant are rarely curative. 20, 21 Regimens used in conventional treatment have rarely proven efficacious for relapse after BMT. While treatment with IFN␣ has been shown to induce cytogenetic remissions in about 20% of untransplanted patients with CML, 22 patients who relapsed after BMT do not respond to IFN␣ treatment. 23 In vitro, IL-2 inhibits the clonogenic growth of CML cell lines in a dose-dependent manner with a reduction of BCR/ABL mRNA accumulation and p210 protein levels. 16 IL-2 activates the immune system after autologous and allogeneic, T cell-depleted BMT.
24,25 IL-2 alone or in combination with IFN␣, may intensify remission and prolong disease-free survival when given for the prevention of relapse post T cell-depleted allogeneic BMT in CML. 10, 11 A successful therapeutic option in patients with recurrent leukemia after marrow transplantation has been provided by adoptive immunotherapy with donor lymphocytes with or without cytokines. The best results have been obtained in patients with cytogenetic or hematologic relapse of CML. 7, 8 Data from Kolb et al 9 in three patients suggested a positive influence of IFN␣ in combination with DLI to induce remission, while multivariate analyses of large CML patient populations do not indicate an altered response rate after application of IFN␣. 7, 8 However, in one case after CBT IFN␣ but not DLI induced remission. 12 Therefore, our patient with relapsed CML after CBT was treated with IL-2 and IFN␣ in addition to DLIs. However, both high-dose IL-2 infusion and low-dose IL-2 s.c. application had to be interrupted because of increasing numbers of immature myeloid cells in the peripheral blood.
Because of the young age and low body weight of the donor, we had to administer less than 1 × 10 7 T cells as proposed by Mackinnon et al 26 in their DLI treatment schedule. Thus patients, who received Ͻ1 × 10 7 T cells/kg developed neither GVL reaction nor GVHD, whereas a T cell count Ͼ1 × 10 7 /kg resulted in GVL and GVHD. 26 Here, no GVHD was observed but rather a pancytopenia (WHO II) and a GVL effect. One reason for this finding could be the combination of DLI and IFN␣.
In patients who relapse post BMT the median time to remission after DLI was 85 days 8 and PCR analysis for BCR/ABL mRNA became negative 12-37 weeks after the last DLI. 7, 8, 26 A similar time course after DLI treatment was observed in our patient. The transient cytogenetic relapse
Bone Marrow Transplantation followed by sustained remission is a relatively infrequent occurrence after allogeneic BMT and DLI. 27 We conclude that DLI is a feasible therapeutic option for patients relapsing after CBT, even when the donor is a small infant. The role of cytokines in supporting remission in this context is not clear. The combination of DLI with IFN␣ was well tolerated in this patient, whereas the combination with IL-2 had to be interrupted because of increasing numbers of immature myeloid cells. Further examinations for molecular relapse were done by quantitative PCR analysis of BCR/ABL mRNA. The patient suffered a second relapse (VNTR: 5% recipient DNA; BCR/ABL transcript positive) 17 months after last DLI. Therefore we will reattempt to treat her with DLI.
